Zymeworks (NASDAQ:ZYME) Trading Up 11.4% After Analyst Upgrade

Posted by George Bondi on Aug 26th, 2026

Zymeworks Inc. (NASDAQ:ZYME – Get Free Report)’s share price shot up 11.4% on Wednesday after HC Wainwright raised their price target on the stock from $51.00 to $55.00. HC Wainwright currently has a buy rating on the stock. Zymeworks traded as high as $29.00 and last traded at $30.6040. 192,270 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 675,212 shares. The stock had previously closed at $27.47.

Several other equities research analysts have also recently weighed in on ZYME. B. Riley Financial reiterated a “buy” rating and issued a $44.00 target price (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a research note on Wednesday. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a report on Friday, August 7th. Finally, Wells Fargo & Company raised their price objective on shares of Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $40.22.

Get Our Latest Report on Zymeworks

More Zymeworks News

Here are the key news stories impacting Zymeworks this week:

Positive Sentiment: The FDA approved two Ziihera-containing regimens for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, expanding the drug’s commercial opportunity and marking zanidatamab’s second FDA approval in less than two years. Zymeworks FDA approval and milestone announcement
Positive Sentiment: The approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, bringing Zymeworks’ total upfront and milestone payments from Jazz to $650 million. The company remains eligible for up to $1.3 billion in additional Jazz milestones and tiered royalties of 10% to 20% on net sales, plus potential payments and royalties under its BeOne Medicines collaboration. Zymeworks $250 million milestone
Positive Sentiment: Citizens JMP reaffirmed a “market outperform” rating and set a $32 price target, while HC Wainwright raised its target to $55 from $51 and maintained a “buy” rating. These targets imply continued upside from the referenced $27.47 share price. Analyst price target updates
Neutral Sentiment: The approval is supported by Phase 3 HERIZON-GEA-01 results, including median overall survival of more than two years; however, additional analyses and an ongoing confirmatory trial remain important for validating long-term clinical benefit.
Negative Sentiment: Zymeworks remains dependent on Jazz and BeOne for commercialization and future milestone payments. Delays, disappointing confirmatory-trial results, safety concerns, or weaker-than-expected Ziihera sales could limit the stock’s upside.

Institutional Trading of Zymeworks

Large investors have recently bought and sold shares of the business. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Zymeworks in the 2nd quarter valued at $508,000. California State Teachers Retirement System increased its holdings in Zymeworks by 2,538.8% during the 2nd quarter. California State Teachers Retirement System now owns 986,628 shares of the company’s stock worth $25,790,000 after purchasing an additional 949,239 shares in the last quarter. Nykredit A S acquired a new stake in shares of Zymeworks in the 2nd quarter valued at about $25,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Zymeworks in the second quarter valued at about $475,000. Finally, Wellington Management Group LLP bought a new stake in shares of Zymeworks in the second quarter valued at about $2,876,000. 92.89% of the stock is owned by institutional investors.

Zymeworks Stock Up 10.0%

The firm has a market capitalization of $2.14 billion, a P/E ratio of -14.95 and a beta of 1.15. The stock has a fifty day moving average of $24.60 and a 200-day moving average of $24.72.

Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The firm had revenue of $3.23 million for the quarter, compared to analyst estimates of $4.54 million. During the same period last year, the company earned $0.03 EPS. The company’s revenue was down 90.6% compared to the same quarter last year. Sell-side analysts predict that Zymeworks Inc. will post 1.25 EPS for the current fiscal year.

Zymeworks declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 14th that authorizes the company to repurchase $125.00 million in shares. This repurchase authorization authorizes the company to buy up to 7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

About Zymeworks

(Get Free Report)

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.